For the quarter ending 2026-03-31, NUVL had -$102,012K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Direct external expenses by program-Zidesamtinib | -37,187 | - | - | - |
| Direct external expenses by program-Neladalkib | -60,036 | - | - | - |
| Direct external expenses by program-NVL-330 | -9,236 | - | - | - |
| Direct external expenses by program-Discovery Programs | -6,039 | - | - | - |
| Personnel-related expenses | -91,524 | - | - | - |
| Stock-based compensation epxense | 28,880 | - | - | - |
| General and administrative professional and consultant fees-General And Administrative Expense | -5,620 | - | - | - |
| Change in fair value of related party revenue share liability | -2,570 | - | - | - |
| Interest income | -20,294 | - | - | - |
| Other segment items | -11,949 | - | - | - |
| Income tax provision | -266 | - | - | - |
| Net loss | -109,279 | -118,705 | -122,437 | -184,235 |
| Stock-based compensation expense | 28,880 | 21,734 | 22,314 | 42,454 |
| Net accretion on marketable securities | 1,830 | 20,284 | -2,187 | -6,990 |
| Change in fair value of related party revenue share liability | -2,570 | -27,940 | -19,810 | -7,470 |
| Other non-cash | -120 | -116 | -99 | -130 |
| Prepaid expenses and other current assets | 3 | 6,646 | -170 | -134 |
| Other assets | 3,036 | -2,584 | 2,131 | 10,961 |
| Accounts payable | -7,688 | 7,814 | 8,668 | 8,117 |
| Accrued expenses and other liabilities | -2,133 | -6,235 | 5,232 | 12,462 |
| Net cash used in operating activities | -92,399 | -73,328 | -70,462 | -131,419 |
| Purchases of marketable securities | 200,963 | 444,043 | 178,472 | 435,251 |
| Proceeds from maturities and sales of marketable securities | 181,549 | 163,100 | 232,443 | 538,146 |
| Net cash provided by (used in) investing activities | -19,414 | -280,943 | 53,971 | 102,895 |
| Proceeds from issuance of common stock, net | 10,135 | 500,640 | 4,773 | 10,309 |
| Payments of equity issuance costs | 334 | 376 | 0 | 6 |
| Payments of insurance costs financed by a third-party | - | 0 | 0 | 0 |
| Net cash provided by financing activities | 9,801 | 500,264 | 4,773 | 10,303 |
| Net decrease in cash and cash equivalents | -102,012 | 145,993 | -11,718 | -18,221 |
| Cash and cash equivalents at beginning of period | 261,745 | 115,752 | 145,691 | - |
| Cash and cash equivalents at end of period | 159,733 | 261,745 | 115,752 | - |
Nuvalent, Inc. (NUVL)
Nuvalent, Inc. (NUVL)